Sun Life Financial’s Rein Therapeutics RNTX Stock Holding History

Sun Life Financial’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,152	Closed	-$253K	–	634
2018 Q3	$253K	Buy	+25,152	New	+$1.69M	0.05%	195

Other funds holding RNTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

JOYN Advisors Atlanta, Georgia $300M AUM 14.91% 1-Year Est. Return

Sun Life Financial's RNTX Position: Q4 2018 in Review

Sun Life Financial sold out of Rein Therapeutics (RNTX) in Q4 2018, closing a stake of 25,152 shares — an estimated $253K sold.

Sun Life Financial first reported a position in RNTX in Q3 2018 and held it in 1 quarter. The position peaked at $253K in Q3 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q4 2018.

Sun Life Financial reported no remaining Rein Therapeutics position as of Q4 2018 after selling out during the quarter.
Sun Life Financial sold 25,152 Rein Therapeutics shares in Q4 2018, an estimated $253K.
Sun Life Financial first reported a position in Rein Therapeutics in Q3 2018 and held it in 1 quarter.
Sun Life Financial's Rein Therapeutics position peaked at $253K in Q3 2018.
23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2018.

Based on Sun Life Financial's 13F filing for Q4 2018, filed 6 Feb 2019.